Instil Bio, Inc. (TIL)
Market Closed
3 Aug, 20:00
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA $
7. 22
+0.1
+1.4045%
$
48.49M Market Cap
- P/E Ratio
- Div Yield
10,246 Volume
-6.35 Eps
$ 7.12
Previous Close Want to track TIL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing.
Seekingalpha | 1 year ago
